Connect with us


MediXall Group, Inc. (MDXL: OTCQB) | MediXall Group, Inc. Completes Milestones, Looks To Launch MediXaid Platform and Expand Sales & Marketing



FT LAUDERDALE, FL–(Marketwired – Nov 14, 2017) – MediXall Group Inc. (OTCQB: MDXL) announced today that several significant milestones have been completed. The Company, which initially targeted the South Florida region, will be the first platform of its kind to address the need for consumer-facing healthcare technology and pricing transparency at a level that meets and exceeds regulatory and professional standards, while offering a familiar and convenient user experience, setting apart from all others.

Since inception, MediXall Group and the development team have finalized the MediXaid Healthcare Platform’s User Interface and User Experience (see demo at and are currently onboarding MRI centers and Chiropractors to the platform, on track for a soft launch with those specialties in Q4 of 2017.

The MediXaid Provider Network’s 4,000+ registered healthcare providers are continuing to complete their legal agreements and the subsequent process of credentialing and onboarding to the MediXaid Platform. The full launch of the MediXaid Healthcare Platform with all medical services available is on track for the first quarter of 2018, including, but not limited to, the following general categories:

  • Physician services including cosmetic services and surgery
  • Dental services including orthodontics, endodontics, and oral surgery, and other physician services
  • Diagnostic services including MRI, MRA, CT Scan, Stress Tests, sonograms and ultrasounds
  • Laboratory services
  • Home healthcare services

MediXall Group deploys a direct sales approach driven by an inside sales team based in Fort Lauderdale, Florida, and Orlando, Florida. The sales team qualifies and manages prospective and current MediXaid Network Providers, aiming to initiate, retain, and expand their use of the platform over time. The sales team partners with the technology team to provide consultation and product demonstration to prospects to accelerate the onboarding of new subscribers. MediXall Group will begin to engage large companies that have healthcare plans for their employees in the first quarter of 2018. MediXall intends to develop and expand a field sales team responsible for discovery, qualification, and account management for larger organizations.

The MediXaid Platform is creating a unified online environment that connects physicians and caregivers to patients, and payers to the caregivers, across all healthcare settings. Starting with pricing transparency, we intend to expand our service offerings to enable smarter care and empower the customer/patient at virtually every point of the healthcare continuum; whether organically, through acquisitions, or through integration with our strategic partners’ solutions. As we expand the Healthcare EcoSystemTM, the MediXaid Healthcare Platform will facilitate such transformation in the future of healthcare by offering community connectivity, interoperability, data analytics, and consumer engagement features and functionality.

MediXall Group CEO, Neil Swartz, stated, “MediXall has put together a very ambitious expansion strategy that we feel is well supported by our operations history so far. The momentum we are building in the marketplace is only going to grow, and we are adding staff and other regional offices to meet this tremendous challenge.”

About MediXall Group, Inc.

MediXall Group is a technology and innovation-driven organization purposefully designed and structured to bring effective change to the U.S. healthcare industry that is actively trading on the OTCQB under the symbol “MDXL.” The Company believes its revolutionary approach will help drive much needed change that it envisions is needed in the current healthcare system. The mission of the MediXall Group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. By approaching the healthcare ecosystem as a whole, MediXall creates, invests and incubates companies that embody its mission statement. MediXall’s first acquisition was MediXaid®, a developing cloud-based software platform that promises to revolutionize the way people purchase healthcare goods and services.

About MediXaid

The first product MediXall is developing is the MediXaid Platform, which is on schedule for a 4th quarter launch. The MediXaid Platform is a new generation healthcare marketplace platform to address the growing need of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. With, patient/clients find price transparency and the ability to make informed choices based on price, location and schedule for requested medical products and services. In this era of rapidly increasing deductibles and healthcare costs, the cloud-based MediXaid platform is designed to be transformational and disruptive to traditional methods of medical care and provisioning of medical services to the consumer.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Specifically, the Company’s ability to raise additional capital, execute its business plan and strategy, sustain or increase gross margins, achieve profitability and build shareholder value are forward looking statements. A more extensive listing of risks and factors that may affect the Company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Orexo AB (ORXOY: OTCQX International) | Orexo completes early redemption of existing bond loan





Orexo completes early redemption of existing bond loan

Nov 22, 2017

OTC Disclosure & News Service

Stockholm, Uppsala, Sweden

This release includes additional documents. Select the link(s) below to view.

Press release Orexo completes early redemption of existing bond loan publ. 22.11.2017.pdf

Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Continue Reading


Orexo AB (ORXOY: OTCQX International) | Orexo Completes Early Redemption of Existing Bond Loan



UPPSALA, Sweden, Nov. 22, 2017 /PRNewswire/ — Orexo AB (publ.) (the “Company”) today announces that the Company, in accordance with Orexo’s press release on 31 October 2017, has completed the early total redemption of the existing bond loan (ISIN SE0005932159).

The redemption was made at an amount corresponding to 101 percent of the nominal amount (i.e. SEK 1,010,000 per bond, the nominal amount being SEK 1,000,000) together with accrued but unpaid interest from the preceding interest payment date on November 9 2017 up to, and including, the redemption date on November 22 2017. In conjunction herewith, the bonds are delisted from the corporate bond list of Nasdaq Stockholm.

For further information, please contact:

Orexo AB   (publ.)

Nikolaj Sørensen, President and CEO                         
Tel: +46 (0)18-780-88-00                                              

Henrik Juuel, EVP and CFO
Tel: + 46 (0)18-780-88-00

About Orexo

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

For more information about Orexo please visit, You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites  and

The information was submitted for publication at 8:30 am CET, November 22, 2017

This information was brought to you by Cision,c2396751

The following files are available for download:


View original content:


Copyright © 2017 PR Newswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Continue Reading

Recent Posts